Surgalign Holdings, formerly RTI Surgical Holdings, announced the closing of the sale of its OEM business to Montagu Private Equity for a total cash consideration of $440 million. Proceeds from the sale will be used to pay down all outstanding indebtedness.
Effective immediately, the company changed its name to Surgalign Holdings and will use ticker symbol SRGA on the NASDAQ. Trading under the new symbol will begin on July 23, 2020. Additionally, the company’s Board of Directors appointed Terry M. Rich to the role of President and CEO effective immediately. Mr. Rich, formerly RTI’s President of Global Spine, steps into the role after the retirement of Camille Farhat.
As a pure-play spine company, Surgalign has positive momentum on the strength of its spinal hardware sales and novel therapies like the coflex Interlaminar Stabilization device. The company’s spine sales grew +20.6% to $119 million in 2019 and continued its positive trajectory into 1Q20 with +11.2% growth.
The OEM business will retain the name RTI Surgical, and continue its focus on tissue, biologics and collaboration with other medical technology companies.
Surgalign Holdings, formerly RTI Surgical Holdings, announced the closing of the sale of its OEM business to Montagu Private Equity for a total cash consideration of $440 million. Proceeds from the sale will be used to pay down all outstanding indebtedness.
Effective immediately, the company changed its name to Surgalign Holdings and...
Surgalign Holdings, formerly RTI Surgical Holdings, announced the closing of the sale of its OEM business to Montagu Private Equity for a total cash consideration of $440 million. Proceeds from the sale will be used to pay down all outstanding indebtedness.
Effective immediately, the company changed its name to Surgalign Holdings and will use ticker symbol SRGA on the NASDAQ. Trading under the new symbol will begin on July 23, 2020. Additionally, the company’s Board of Directors appointed Terry M. Rich to the role of President and CEO effective immediately. Mr. Rich, formerly RTI’s President of Global Spine, steps into the role after the retirement of Camille Farhat.
As a pure-play spine company, Surgalign has positive momentum on the strength of its spinal hardware sales and novel therapies like the coflex Interlaminar Stabilization device. The company’s spine sales grew +20.6% to $119 million in 2019 and continued its positive trajectory into 1Q20 with +11.2% growth.
The OEM business will retain the name RTI Surgical, and continue its focus on tissue, biologics and collaboration with other medical technology companies.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
